Telehealth after the pandemic: Will the inverse care law apply?


Posted: 2021-09-15 19:00:00
J Cyst Fibros . 2021 Sep 11;S1569-1993(21)01364-3. doi: 10.1016/j.jcf.2021.08.023. Online ahead of print. Affiliations Expand Affiliations 1 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Queens Medical Centre, UK. Electronic address: Rebecca.calthorpe@nottingham.ac.uk. 2 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Queens Medical Centre, UK. Item in Clipboard Rebecca J Calthorpe et al. J Cyst Fibros. 2021. Show details Display options Display options Format J Cyst Fibros . 2021 Sep 11;S1569-1993(21)01364-3. doi: 10.1016/j.jcf.2021.08.023. Online ahead of print. Affiliations 1 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Queens Medical Centre, UK. Electronic address: Rebecca.calthorpe@nottingham.ac.uk. 2 Division of Child Health, Obstetrics & Gynaecology, University of Nottingham, Queens Medical Centre, UK. Item in Clipboard CiteDisplay options Display options Format Abstract The Covid-19 pandemic has accelerated the use of telehealth within the cystic fibrosis (CF) community to deliver CF care. The article by Solomon and colleagues exploring the patient and family experiences of telehealth care delivery, as part of the CF chronic care model in the US, is therefore timely. In this commentary, we discuss how the US experience of telehealth care compares with reports from CF centres in other parts of the world. We highlight the potential challenges, including whether the inverse care law will apply in this new era of CF telehealth. Keywords: Covid-19; Cystic fibrosis; Telehealth; Telemedicine. Copyright © 2021 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved. Conflict of interest statement Declaration of Competing Interest R.C has no conflicts of interest. Outside the submitted work, A.S reports grants from Vertex and reports speaker honoraria and expenses from TEVA and Vertex. A.S reports membership of the US CF Foundation therapeutic development network data safety monitoring board. A.R. Smyth has a patent “Alkyl quinolones as biomarkers of Pseudomonas aeruginosa infection and uses thereof” issued. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19


Powered by Vergleichsportal